Updates are available Correction dated 2025-01-31
Click to view Correction: https://doi.org/10.1038/s41591-025-03541-w
-
Authors
Wang, Yeming
Wang, Hong
Zhang, Yu
Ma, Anlin
Liu, Dong
Li, Xiaoguang
Yang, Guoru
Deng, Min
Wang, Shaofang
Liu, Yuanyuan
Liu, Chuanmiao
Ge, Fangqi
Wang, Sikui
Yu, Yunsong
Feng, Ganzhu
Xiao, Zuke
Li, Xing
Sun, Yilan
Chen, Xuyan
Cao, Zhaolong
Ding, Yan
Wu, Xiaoping
Wei, Jun
- License Information
-
More Information
Article History
Received: 2 June 2024
Accepted: 13 November 2024
First Online: 7 January 2025
Change Date: 31 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03541-w
Competing interests
: The clinical trial titled ‘Severe Influenza Trial of Arbidol’ (ClinicalTrials.gov registration: ) has received support from Shijiazhuang No.4 Pharmaceutical.
